Pharmaids Pharmaceuticals Ltd

On 03-Dec, Pharmaids Pharmaceuticals Ltd witnessed a notable rise in its share price, climbing 3.82% to close at ₹49.50. This upward movement reflects a combination of recent positive trading momentum and heightened investor participation, despite the stock's longer-term underperformance relative to the broader market.

As of 17-Nov, Pharmaids Pharmaceuticals Ltd is currently priced at Rs 47.82, reflecting a 7.68% increase today, despite a 1.24% decline over the past week and a 32.15% drop year-to-date. While it has outperformed its sector today, the decrease in investor participation may indicate caution moving forward.

As of 14-Nov, Pharmaids Pharmaceuticals Ltd's stock price is Rs 44.13, down 3.67%, and significantly underperforming compared to its sector and the broader market. The stock is trading below all moving averages, with a year-to-date return down 37.39% and nearing its 52-week low.

Pharmaids Pharma has seen net sales grow to 19.45 Cr in March 2025 from 0.00 Cr in March 2023, but continues to report significant losses, with an operating profit of -12.66 Cr and a profit after tax of -13.51 Cr in March 2025, alongside rising total assets and liabilities. Cash flow from operating activities remains negative at -13.00 Cr, indicating ongoing financial challenges.

Pharmaids Pharmaceuticals reported strong revenue growth of 64.31% year-on-year, reaching ₹8.61 crores in Q2 FY26, but continues to face significant operational challenges with a net loss of ₹2.48 crores and a negative operating margin of -61.67%. While the revenue increase is positive, ongoing financial struggles and a deteriorating capital structure present substantial risks.

The next results date for Pharmaids Pharma is 11 November 2025.

As of 06-Nov, Pharmaids Pharmaceuticals Ltd's stock price is Rs 46.64, down 3.26%, and has underperformed significantly against the Sensex, with a year-to-date decline of 33.83%. The stock is trading below all major moving averages, indicating a bearish trend amid high volatility and investor uncertainty.

As of 23-Oct, Pharmaids Pharmaceuticals Ltd is seeing a price increase to Rs 49.96, up 2.78%, but has declined 13.85% over the past month. Despite recent gains, the stock has outperformed the benchmark significantly over the long term, with a 1-year return of 40.73%.

As of 15-Oct, Pharmaids Pharmaceuticals Ltd is currently priced at Rs 47.46, reflecting a 6.22% increase today. Despite recent volatility and short-term declines, the stock has historically outperformed the benchmark Sensex over a longer period, indicating potential resilience.

As of 10-Oct, Pharmaids Pharmaceuticals Ltd's stock price is Rs 44.01, down 6.46% and has fallen 27.83% over the last nine days. The stock is underperforming significantly compared to the Sensex, with a year-to-date decline of 37.56%, indicating waning investor confidence.

As of 08-Oct, Pharmaids Pharmaceuticals Ltd's stock price is Rs 49.00, down 6.18%, with a significant decline of 19.65% over the past week and 30.48% year-to-date. The stock is underperforming compared to the Sensex, indicating broader market challenges and a bearish trend.

As of 07-Oct, Pharmaids Pharmaceuticals Ltd is facing a significant decline in its stock price, currently at Rs 53.90, down 3.85%. The stock has underperformed over the past week and year-to-date, with a notable decrease in investor participation and high volatility.

As of 01-Oct, Pharmaids Pharmaceuticals Ltd is facing a slight decline in stock price, currently at 59.40, with a total decline of 2.59% over the last three days. Despite strong long-term performance, challenges such as operating losses and decreased investor participation are impacting its short-term outlook.

As of 08-Sep, Pharmaids Pharmaceuticals Ltd's stock price is declining at 61.50, down 0.4%, with a total drop of 1.09% over the last two days. Despite strong long-term returns, recent operating losses and a high debt-to-EBITDA ratio are negatively impacting investor interest and contributing to the stock's downward trend.

As of 05-Sep, Pharmaids Pharmaceuticals Ltd's stock price is declining at 61.75, down 0.69%, and has underperformed its sector today. Despite a positive return of 5.27% over the past week, it has a year-to-date decline of 12.39%, indicating mixed performance amid decreasing investor participation.

As of 04-Sep, Pharmaids Pharmaceuticals Ltd is priced at 62.18, with a slight increase of 0.05%. Despite a strong long-term performance, the company faces challenges such as operating losses and high debt, leading to declining investor interest and caution for future investments.

As of 03-Sep, Pharmaids Pharmaceuticals Ltd's stock price is declining at 62.15, down 1.19%, and has underperformed its sector. The company faces operational losses and high debt, contributing to a year-to-date drop of 11.82%, despite a strong annual performance of 52.70%.

As of 02-Sep, Pharmaids Pharmaceuticals Ltd is currently priced at Rs 62.90, reflecting a 3.28% increase, but it has weak long-term fundamentals with operating losses and a negative EBITDA. Despite recent short-term gains, the stock has declined 10.75% year-to-date, raising concerns about its financial sustainability.